Concepedia

Koo Wilson

KW

Statistics

Publications

19

Citations

593

H-Index

16

Active since

2003

Affiliations

Pfizer (United Kingdom)(Current)

Swedish Orphan Biovitrum (Sweden)

Pfizer (United States)

Pfizer (Sweden)

Apellis Pharmaceuticals (United States)

Koo Wilson is an author at Pfizer (United Kingdom) specializing in pharmacy, pharmacoeconomics, and cost-effectiveness analysis.

Publications per year

2003–2022

19

Publications

19

The Economic Burden of Stroke in the United Kingdom

Penny Youman, Koo Wilson, F Harraf et al. · PharmacoEconomics · 2003 · 153 citations

, , +14

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries

Kristian Bolin, Koo Wilson, H. Benhaddi et al. · European Journal of Public Health · 2009 · 50 citations · Full text

, , +17

The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving <scp>C5</scp> inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life

Jens Panse, Flore Sicre de Fontbrune, Pascale Burmester et al. · European Journal Of Haematology · 2022 · 37 citations · Full text

, , +6

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

Dawn Lee, Koo Wilson, Ron Akehurst et al. · Heart · 2014 · 33 citations · Full text

, , +17

Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden

Nathaniel Henry, Jelena Jovanović, Max Schlueter et al. · Journal of Medical Economics · 2017 · 32 citations · Full text

, , +12

1–5 of 19